Newron Pharmaceuticals S.p.A. (NP5.DE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Stefan Weber | CEO & Executive Director | 475k | -- | 1965 |
| Mr. Roberto Galli | Chief Financial Officer | -- | -- | -- |
| Mr. Filippo Moriggia | Vice President of Operations | -- | -- | -- |
| Dr. Ravi Anand M.D., Ph.D. | Chief Medical Officer | 1.23M | -- | 1957 |
| Ms. Laura Faravelli | Vice President of Business Development | -- | -- | -- |
Newron Pharmaceuticals S.p.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 22
Description
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Corporate Governance
Upcoming Events
April 14, 2025 at 10:59 AM UTC
Newron Pharmaceuticals S.p.A. Earnings Date
Recent Events
Recent Events Information Not Available